ea0094p246 | Neuroendocrinology and Pituitary | SFEBES2023
Sakthivel Pavithra
, Wong Anson
, Criseno Sherwin
, Toogood Andrew
Background: In the UK, adults with growth hormone deficiency (GHD) are treated with recombinant Growth Hormone (GH) therapy according to NICE guidelines (TA64). Provided that patients show an initial improvement in their quality-of-life score, assessed using the Quality-of-Life Assessment of GHD in Adults (Qol-AGHDA) questionnaire, they can continue with their GH treatment long-term. However, in clinical practice, many patients are observed to discontinue GH r...